### SiHa

no drug



G3BP1 eIF3b eIF4G 250 µM CisPt



G3BP1 eIF3b eIF4G merge

250 µM CisPt

100 µM SA





G3BP1 eIF3b eIF4G

merge

#### **MES-SA**

no drug

G3BP1 eIF3b eIF4G merge

G3BP1 eIF3b eIF4G merge 100 µM SA

no drug



G3BP1 eIF3b eIF4G G3BP1

merge

eIF3b

merge

G3BP1 eIF3b

eIF4G merge

10 µm

### Figure S1

250 µM CisPt

HeLa





eIF4G



100 µM SA



G3BP1 p70 S6

G3BP1 p70 S6

TIAR

TIAR G3BP1

p70 S6 TIAR

B



TIAR G3BP1 PELO



TIAR G3BP1 PELO



PELO TIAR



ABCE1 TIAR

G3BP1 ABCE1



#### G3BP1 ABCE1

TIAR

TIAR

no drug





G3BP1 FXR1 **CAPRIN1** 





#### ΔHRI

250 µM CisPt

100 µM SA

#### $\Delta \mathbf{PKR}$

250 µM CisPt



ΔPERK

 $\Delta GCN2$ 

100 µM SA

100 µM SA

250 µM CisPt

250 µM CisPt











HAP1-∆HRI	TG C TG G AG CAC T TG AG C CACG TG CATG AAC CAAAC G T T CAAG ACAG G T G T TTAAG C G T AAG TAAG AATAAA
HAP1-ΔGCN2	240 250 260 270 280 280 290 300 CCCCTG AAATCAATTTAK TITIGTACMCYCAAGAG G CCTAACTG G TG AAGAAG TATATG TAAAAG TG G ATTTG AG G G CCCAGGAAGAAG TATATG TAAAAG TG G ATTTG AG G G C CCGAAGTAG CAATTTAK TITIGTACMCYCAAGAG G CCTAACTG G TG AAGAAG TATATG TAAAAG TG G ATTTG AG G G C CCCAGGAATCAATTTAKTTTGTACCCTCAAGAG CCCTAACTGGTGAAGAAGTATATGTAAAAGTGGATTTGAGGGTTAAATGCCCAC CTGAAATCAATTTAKTTTGTACCCTCAAG - GCCTAACTGGTGAAGAAGTATATGTAAAAGTGGATTTGAGGGTTAAATGCCCACC
HAP1-ΔPKR	80 90 100 110 120 130 140 150 ACT CACCT I CTTTT CCTTAT TAA GTAT CT CAACAG CTAAT TT KKT G CTTY Y TT CTT G AT CTACCT I CACCT I C
HAP1-ΔPERK	AAAGGTGCTTTCAATAAATCCGGCTCTCGTTTCCATGTCTGGAATATACCGAAGTTCCAAGTGGCCAACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCACACTGAAATCCCACCTTAA